Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity.

Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, Kim DW, Lee JS, Heo DS.

ESMO Open. 2018 Jul 25;3(5):e000332. doi: 10.1136/esmoopen-2018-000332. eCollection 2018.

2.

TRIUMPH Trial: One Small Step Could Become One Giant Leap for Precision Oncology in Head and Neck Cancer.

Keam B, Kim HR, Yoon HJ.

Cancer Res Treat. 2018 Jul 31. doi: 10.4143/crt.2018.335. [Epub ahead of print] No abstract available.

3.

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, Gould M, Yang P, Keefe SM, Piha-Paul SA.

Ann Oncol. 2018 Aug 1;29(8):1807-1813. doi: 10.1093/annonc/mdy232.

PMID:
29992241
4.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R.

Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.

PMID:
29955135
5.

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.

Korean J Intern Med. 2018 Jun 29. doi: 10.3904/kjim.2018.011. [Epub ahead of print]

6.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF.

Cancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30.

PMID:
29848605
7.

Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.

Lee SY, Choi YS, Song IC, Park SG, Keam B, Yang YJ, Song EK, Lee HJ, Cho SH, Shim H, Park KU, Lee KH, Jo DY, Jo IS, Yun HJ; Korean South West Oncology Group (KSWOG) investigators.

Medicine (Baltimore). 2018 May;97(21):e10778. doi: 10.1097/MD.0000000000010778.

8.

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.

Lim SM, Cho SH, Hwang IG, Choi JW, Chang H, Ahn MJ, Park KU, Kim JW, Ko YH, Ahn HK, Cho BC, Nam BH, Chun SH, Hong JH, Kwon JH, Choi JG, Kang EJ, Yun T, Lee KW, Kim JH, Kim JS, Lee HW, Kim MK, Jung D, Kim JE, Keam B, Yun HJ, Kim S, Kim HR.

Cancer Res Treat. 2018 May 9. doi: 10.4143/crt.2018.012. [Epub ahead of print]

9.

Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.

Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS.

Thorac Cancer. 2018 Jun;9(6):736-744. doi: 10.1111/1759-7714.12641. Epub 2018 Apr 22.

PMID:
29682899
10.

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy.

Choi JY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Jo SJ.

Cancer Res Treat. 2018 Apr 5. doi: 10.4143/crt.2017.491. [Epub ahead of print]

11.

Cancer Pain Management Education Rectifies Patients' Misconceptions of Cancer Pain, Reduces Pain, and Improves Quality of Life.

Koh SJ, Keam B, Hyun MK, Ju Seo J, Uk Park K, Oh SY, Ahn J, Lee JY, Kim J.

Pain Med. 2018 Mar 26. doi: 10.1093/pm/pny039. [Epub ahead of print]

PMID:
29590446
12.

Attitudes toward early palliative care in cancer patients and caregivers: a Korean nationwide survey.

Yoo SH, Kim M, Yun YH, Keam B, Kim YA, Kim YJ, Shim HJ, Song EK, Kang JH, Kwon JH, Lee JL, Lee SN, Kim SY, Kang EJ, Do YR, Choi YS, Jung KH.

Cancer Med. 2018 May;7(5):1784-1793. doi: 10.1002/cam4.1441. Epub 2018 Mar 25.

13.

Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance.

Suh KJ, Kim KH, Kim R, Byun JM, Kim M, Park JH, Keam B, Kim TM, Kim JS, Choi IS, Heo DS.

Korean J Intern Med. 2018 Feb 23. doi: 10.3904/kjim.2017.174. [Epub ahead of print]

14.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B.

Am J Clin Oncol. 2018 Feb 21. doi: 10.1097/COC.0000000000000429. [Epub ahead of print]

PMID:
29462123
15.

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.

Jo J, Kim SH, Kim YJ, Lee J, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Chung JH, Jeon YK, Lee JS.

Yonsei Med J. 2018 Mar;59(2):202-210. doi: 10.3349/ymj.2018.59.2.202.

16.

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.

Park S, Ha S, Lee SH, Paeng JC, Keam B, Kim TM, Kim DW, Heo DS.

PLoS One. 2018 Jan 31;13(1):e0189766. doi: 10.1371/journal.pone.0189766. eCollection 2018.

17.

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.

Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.

PMID:
29326030
18.

Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.

Tahara M, Muro K, Hasegawa Y, Chung HC, Lin CC, Keam B, Takahashi K, Cheng JD, Bang YJ.

Cancer Sci. 2018 Mar;109(3):771-776. doi: 10.1111/cas.13480. Epub 2018 Feb 8.

19.

The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study.

Lee J, Lim J, Park JS, Kim M, Kim TY, Kim TM, Lee KH, Keam B, Han SW, Mun JH, Cho KH, Jo SJ.

Cancer Res Treat. 2017 Dec 14. doi: 10.4143/crt.2017.435. [Epub ahead of print]

20.

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.

Ock CY, Kim S, Keam B, Kim S, Ahn YO, Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS.

Oncotarget. 2017 Jun 16;8(58):97920-97927. doi: 10.18632/oncotarget.18542. eCollection 2017 Nov 17.

21.

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.

Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS.

Cancer Immunol Immunother. 2018 Mar;67(3):459-470. doi: 10.1007/s00262-017-2092-x. Epub 2017 Dec 4.

PMID:
29204702
22.

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.

Cho KM, Keam B, Ha H, Kim M, Jung JW, Song WJ, Kim TM, Jeon YK, Kang HR, Kim DW, Kim CW, Heo DS.

Korean J Intern Med. 2017 Nov 20. doi: 10.3904/kjim.2017.036. [Epub ahead of print]

23.

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.

Kim H, Park CM, Keam B, Park SJ, Kim M, Kim TM, Kim DW, Heo DS, Goo JM.

PLoS One. 2017 Nov 3;12(11):e0187500. doi: 10.1371/journal.pone.0187500. eCollection 2017.

24.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B.

J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26.

25.

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.

Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS.

Nat Commun. 2017 Oct 19;8(1):1050. doi: 10.1038/s41467-017-01018-0.

26.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T.

Ann Oncol. 2017 Nov 1;28(11):2754-2760. doi: 10.1093/annonc/mdx493.

PMID:
28950297
27.

Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection.

Kim H, Chae KJ, Yoon SH, Kim M, Keam B, Kim TM, Kim DW, Goo JM, Park CM.

Eur Radiol. 2018 Feb;28(2):861-868. doi: 10.1007/s00330-017-5006-6. Epub 2017 Aug 7.

PMID:
28786010
28.

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer.

Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS.

Cancer Res Treat. 2018 Jul;50(3):720-728. doi: 10.4143/crt.2017.169. Epub 2017 Jul 14.

29.

Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives.

Koh SJ, Kim S, Kim J, Keam B, Heo DS, Lee KH, Kim BS, Kim JH, Chang HJ, Baek SK.

Cancer Res Treat. 2018 Apr;50(2):614-623. doi: 10.4143/crt.2016.446. Epub 2017 Jul 3.

30.

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.

Kim HJ, Ock CY, Kim TM, Lee SH, Lee JY, Jung SH, Cho YS, Kim M, Keam B, Kim DW, Kim IH, Heo DS.

Cancer Res Treat. 2018 Jul;50(3):670-680. doi: 10.4143/crt.2017.051. Epub 2017 Jul 3.

31.

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, An Y, Keam B, Kim DW, Heo DS, Kim YT, Kim JS, Kim SH, Lee JS, Lee SH, Park K, Ku JL, Jeon YK, Chung DH, Park PJ, Kim J, Kim TM, Ju YS.

J Clin Oncol. 2017 Sep 10;35(26):3065-3074. doi: 10.1200/JCO.2016.71.9096. Epub 2017 May 12.

PMID:
28498782
32.

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.

Park S, Kim JY, Lee SH, Suh B, Keam B, Kim TM, Kim DW, Heo DS.

Korean J Intern Med. 2017 May;32(3):514-522. doi: 10.3904/kjim.2015.299. Epub 2017 Apr 14.

33.

Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate.

Lim Y, Lim JM, Jeong WJ, Lee KH, Keam B, Kim TY, Kim TM, Han SW, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Im SA.

Cancer Res Treat. 2017 Oct;49(4):1033-1043. doi: 10.4143/crt.2016.413. Epub 2017 Apr 7.

34.

MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.

Kwon D, Koh J, Kim S, Go H, Kim YA, Keam B, Kim TM, Kim DW, Jeon YK, Chung DH.

Lung Cancer. 2017 Apr;106:131-137. doi: 10.1016/j.lungcan.2017.02.008. Epub 2017 Feb 16.

PMID:
28285687
35.

Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.

Sim SH, Kim S, Kim TM, Jeon YK, Nam SJ, Ahn YO, Keam B, Park HH, Kim DW, Kim CW, Heo DS.

Am J Pathol. 2017 May;187(5):980-986. doi: 10.1016/j.ajpath.2017.01.004. Epub 2017 Mar 9.

PMID:
28284718
36.

A Case of Nuclear Protein in Testis Midline Carcinoma Arising From the Submandibular Gland Duct in a Pregnant Patient.

Cho Y, Keam BS, Jung KC, Kim BH.

J Oral Maxillofac Surg. 2017 Sep;75(9):2020-2024. doi: 10.1016/j.joms.2017.02.002. Epub 2017 Feb 14.

PMID:
28282518
37.

Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.

Kim S, Koh J, Kwon D, Keam B, Go H, Kim YA, Jeon YK, Chung DH.

Eur J Cancer. 2017 Apr;75:141-149. doi: 10.1016/j.ejca.2017.01.004. Epub 2017 Feb 20.

PMID:
28222308
38.

Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma.

Lee JK, Louzada S, An Y, Kim SY, Kim S, Youk J, Park S, Koo SH, Keam B, Jeon YK, Ku JL, Yang F, Kim TM, Ju YS.

Ann Oncol. 2017 Apr 1;28(4):890-897. doi: 10.1093/annonc/mdw686.

39.

Reply to Influenza vaccination in patients with cancer.

Keam B, Kim MK, Park WB.

Cancer. 2017 Apr 1;123(7):1273. doi: 10.1002/cncr.30611. Epub 2017 Feb 9. No abstract available.

40.

Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.

Lim YJ, Chang JH, Kim HJ, Keam B, Kim TM, Kim DW, Paeng JC, Kang KW, Chung JK, Jeon YK, Chung DH, Wu HG.

Clin Lung Cancer. 2017 May;18(3):e169-e178. doi: 10.1016/j.cllc.2016.12.013. Epub 2016 Dec 28.

PMID:
28131636
41.

Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).

Kim Y, Lee SJ, Lee JY, Lee SH, Sun JM, Park K, An HJ, Cho JY, Kang EJ, Lee HY, Kim J, Keam B, Kim HR, Lee KE, Choi MY, Lee KH, Ahn MJ.

Cancer. 2017 Jun 1;123(11):1958-1964. doi: 10.1002/cncr.30537. Epub 2017 Jan 19.

42.

Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles.

Keam B, Kim MK, Choi Y, Choi SJ, Choe PG, Lee KH, Kim TM, Kim TY, Oh DY, Kim DW, Im SA, Kim NJ, Heo DS, Park WB, Oh MD.

Cancer. 2017 Mar 1;123(5):841-848. doi: 10.1002/cncr.30468. Epub 2016 Dec 20.

43.

Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma.

Kwon D, Yun JY, Keam B, Kim YT, Jeon YK.

World J Gastroenterol. 2016 Nov 28;22(44):9803-9812.

44.

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer.

Shin J, Keam B, Kim M, Park YS, Kim TM, Kim DW, Kim YW, Heo DS.

J Thorac Oncol. 2017 Mar;12(3):520-528. doi: 10.1016/j.jtho.2016.11.2216. Epub 2016 Nov 17.

45.

Implication of Tumor Location for Lymph Node Metastasis in Maxillary Sinus Carcinoma: Indications for Elective Neck Treatment.

Jeon SH, Han DH, Won TB, Keam B, Kim JH, Wu HG.

J Oral Maxillofac Surg. 2017 Apr;75(4):858-866. doi: 10.1016/j.joms.2016.10.004. Epub 2016 Oct 13.

PMID:
27818080
46.

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.

Park S, Park S, Lee SH, Suh B, Keam B, Kim TM, Kim DW, Kim YW, Heo DS.

Korean J Intern Med. 2016 Nov;31(6):1140-1149. Epub 2016 Mar 28.

47.

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.

Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, Min HS, Jeon YK, Park K.

Ann Oncol. 2017 Feb 1;28(2):292-297. doi: 10.1093/annonc/mdw559.

PMID:
27803005
48.

Optimal design and endpoint of clinical trials using immune checkpoint blocking agents.

Keam B, Jung H, Nam BH.

Expert Rev Anticancer Ther. 2016 Dec;16(12):1217-1218. Epub 2016 Oct 28. No abstract available.

PMID:
27740862
49.

Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.

Kim R, Keam B, Kwon D, Ock CY, Kim M, Kim TM, Kim HJ, Jeon YK, Park IK, Kang CH, Kim DW, Kim YT, Heo DS.

World J Gastroenterol. 2016 Oct 7;22(37):8389-8397.

50.

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY.

J Clin Oncol. 2016 Nov 10;34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478. Epub 2016 Sep 30.

PMID:
27646946

Supplemental Content

Support Center